Advancing the Diagnostic-to-Treatment Continuum in Cancer Care –
Pittsburgh

Pittsburgh will bring together leading voices in oncology, hematology, pathology, molecular diagnostics, and translational science for a multidisciplinary program focused on the advances transforming precision cancer care.

The 2027 program will once again be chaired by Marija Balic, MD, PhD, MBA, and Adrian V. Lee, PhD, building on the collaborative foundation established through the Pittsburgh conference. Together, they bring complementary perspectives across clinical oncology, translational research, molecular medicine, biomarker discovery, and precision cancer care, reflecting the multidisciplinary approach at the heart of the program.

The conference will explore how emerging biomarkers, molecular and genomic profiling, evolving disease biology, and novel therapies are changing the way cancer is diagnosed, characterized, monitored, and treated across both solid tumors and hematologic malignancies.

Through expert-led presentations, interactive panel discussions, and clinically relevant education, attendees will examine advances across multiple tumor types while exploring the expanding role of precision diagnostics, biomarker-guided treatment, and molecularly informed care in everyday clinical practice.

Key areas of focus will include targeted therapies, immunotherapy, genomic and molecular testing, liquid biopsy and ctDNA, measurable residual disease (MRD), treatment resistance, emerging diagnostic technologies, and novel therapeutic strategies – with an emphasis on translating rapidly evolving science into meaningful clinical decisions.

By bringing together specialists across diagnosis, molecular characterization, translational research, and treatment, the Pittsburgh conference creates a collaborative environment for examining the full diagnostic-to-treatment continuum and the innovations shaping the future of precision cancer care.